2. UroToday Home
  3. Conference Highlights
  4. 2017 International Bladder Cancer Network

IBCN 2017: Bladder Cancer Pipeline- Is there a role for Blue Light Flexible Cystoscopy in the surveillance of Non-Muscle Invasive Bladder Cancer? Results of a prospective multicenter trial

Lisbon, Portugal (UroToday.com) Kamal Pohar from The Ohio State University Columbus, OH presented recent data regarding blue light flexible cystoscopy. This phase III prospective trial assessed patients with non-muscle invasive bladder cancer (NMIBC). Total of 304 patients enrolled in 17 centers. There were 2 possible study procedures: surveillance flexible cystoscopy with white and blue light using Cysview or exam by rigid assessed with white and blue light using Cysview. All lesions identified via either white or blue light went on to have resection. Central pathology consensus read for histological confirmation of cancer. Primary endpoint was to determine proportion of patients identified by blue light only. Patients included were intermediate and high risk NMIBC. 66% of patients had either BCG or intravesical chemotherapy prior to surveillance cystoscopy. Only one of 103 patients taken to OR blue light identified did not have cancer. Overall, 20% had patients confirmed cancer identified only with blue light. Proportion of patients identified only by blue light with carcinoma in situ was 34.6%. A total of 46% had additional tumors identified by blue light cystoscopy and none of those patients had a positive cytology. The false-positive rate for blue light was 9%. Minimal toxicity was observed without any major toxicity noted.

These findings suggest the utility of blue light flexible cystoscopy to improve detection of bladder cancer and surveillance.

Speaker(s): Kamal Pohar, The Ohio State University

Written by: Stephen B. Williams, M.D., Associate Professor, Division of Urology, The University of Texas Medical Branch, Galveston, TX. and Ashish M. Kamat, M.D. Professor, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX., at the International Bladder Cancer Network - October 21, 2017- Lisbon, Portugal